Posts with tag: technology
Waters Corp forecasts Q1 profit below estimates due to a strong dollar; shares down 10% premarket.
Published on: February 12, 2025, 01:09 PM UTC
NiSource Inc. (NI) reported fourth-quarter profit of $223.9 million, or 47 cents per share. Adjusted earnings came to 49 cents per share, on revenue of $1.59 billion.
Published on: February 12, 2025, 01:08 PM UTC
Camtek's Q4 profit beats expectations, with earnings of $0.77 per share and revenue of $117.3 million, exceeding analysts' estimates. For the current quarter, Camtek anticipates revenue between $118 and $120 million.
Published on: February 12, 2025, 01:07 PM UTC
Anavex Life Sciences (AVXL) reported a $12.1 million loss in Q1, a 14-cent loss per share. AVXL shares have fallen 23% YTD, but have risen 35% in the past year.
Published on: February 12, 2025, 01:06 PM UTC
Kornit Digital Ltd. (KRNT) reports Q4 net income of $2.2 million, or 5 cents per share, on revenue of $60.7 million. Adjusted earnings were 18 cents per share.
Published on: February 12, 2025, 01:05 PM UTC
CME Group reports increased hedging activity in Q4, boosting profit by 6% to $1.53 billion, driven by geopolitical and economic uncertainty.
Published on: February 12, 2025, 01:04 PM UTC
Tesla Stock Falls as Elon Musk's OpenAI Bid Raises Concerns about Distraction and Valuation Discord
Published on: February 12, 2025, 01:01 PM UTC
Waters Corp beats estimates with $4.10 earnings per share in Q4 on revenue of $872.7 million
Published on: February 12, 2025, 12:07 PM UTC
Generac Holdings Inc. (GNRC) reported fourth-quarter net income of $117.2 million, beating Wall Street expectations. Adjusted earnings came to $2.80 per share, on revenue of $1.23 billion, meeting forecasts. For the year, GNRC reported profit of $316.3 million, or $5.39 per share, on revenue of $4.3 billion.
Published on: February 12, 2025, 12:06 PM UTC
Biogen forecasts below-expected 2025 profit, hurt by competition and a strong dollar. Stock falls 3% pre-market as investors sell due to slow launch of Leqembi, leading to concerns of slowing sales growth. Despite cost-cutting measures and acquisitions, Biogen predicts a mid-single-digit revenue decline in 2025, with adjusted earnings per share between $15.25 and $16.25, below analysts' estimates of $16.34.
Published on: February 12, 2025, 12:03 PM UTC